Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.

Abstract

Treatment options for primary cutaneous aspergillosis in neonates are limited by the lack of pharmacokinetic and safety data of newer antifungal agents that are effective against Aspergillus spp. We report the successful treatment of cutaneous aspergillosis in an extremely low-birth-weight preterm infant with liposomal amphotericin B, voriconazole and micafungin, and provide pharmacokinetic profiles for voriconazole and micafungin.

• Authors: Roberto P Santos, Pablo J Sánchez, Asuncion Mejias, Daniel K Benjamin Jr, Thomas J Walsh, Sanjay Patel, Hasan S Jafri
• Journal: The Pediatric infectious disease journal (Pediatr Infect Dis J) Vol. 26 Issue 4 Pg. 364-6 (Apr 2007) ISSN: 0891-3668 [Print] United States
• PMID: 17414408 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Antifungal Agents
• Echinocandins
• Lipopeptides
• Lipoproteins
• Peptides, Cyclic
• Pyrimidines
• Triazoles
• liposomal amphotericin B
• Amphotericin B
• Voriconazole
• Micafungin

Topics

• Amphotericin B (therapeutic use)
• Antifungal Agents (therapeutic use)
• Aspergillosis (drug therapy, microbiology)
• Dermatomycoses (drug therapy, microbiology)
• Echinocandins
• Humans
• Infant, Extremely Low Birth Weight
• Infant, Newborn
• Infant, Premature
• Infant, Premature, Diseases (drug therapy, microbiology)
• Lipopeptides
• Lipoproteins (therapeutic use)
• Micafungin
• Peptides, Cyclic (therapeutic use)
• Pyrimidines (therapeutic use)
• Treatment Outcome
• Triazoles (therapeutic use)
• Voriconazole